Jiangsu Kanion Pharmaceutical

Jiangsu Kanion Pharmaceutical is a company listed under the stock ticker 600557 (CN).

View the org chart displaying its 19 main executives

Most searched biographies at Jiangsu Kanion Pharmaceutical

• Xiao Wei, Chairman Of The Board, General Manager and Chief Engineer
• Yin Yang, Vice Chairman of the Board
• Haixin Gao, Director

Create your alert
to follow the executive moves at Jiangsu Kanion Pharmaceutical.

Jiangsu Kanion Pharmaceutical has 1,863 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).
• Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director at Dirk Rossmann
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma

Learn more about the Pharmaceuticals industry >

Press releases by Jiangsu Kanion Pharmaceutical

Social media about Jiangsu Kanion Pharmaceutical

• Jiangsu Kanion Pharmaceutical on Wikipedia, Google News & Yahoo Finance
• Jiangsu Kanion Pharmaceutical on LinkedIn, Twitter & YouTube

Contact by email its executives including Haixin Gao

Call Jiangsu Kanion Pharmaceutical at +86 518 ...

View the org chart

Register to receive your alert

Report an error